Literature DB >> 33506816

Combining Deroofing with LAight® Therapy for Long-Term Disease Control of Hurley Stage II Hidradenitis Suppurativa: Case Report.

Michael Schultheis1, Margot Scheuern2, Ivan Radkov3.   

Abstract

There is an increasing consensus that the treatment of Hidradenitis suppurativa (HS) significantly varies with the degree of inflammation and that treatment according to guidelines is not always successful. Here, we report the case of a 31-year-old male with widespread, highly inflammatory Hurley Stage II HS in multiple locations who failed to respond to any kind of established medical treatment, including biologics. As an alternative approach, Ustekinumab was maintained, and additionally the patient was treated with LAight therapy, a combination of intense pulsed light and radiofrequency. After 10 sessions, deroofing of multiple lesions was performed in a two-step process. After a few weeks of healing time accompanied by specialized wound experts, the patient continued with LAight therapy to control and prevent recurrence. This case shows that the combination of LAight therapy and deroofing is a promising treatment plan for the long-term symptom control of mild and moderate HS.

Entities:  

Keywords:  LAight therapy; acne inversa; case report; deroofing; hidradenitis suppurativa

Year:  2021        PMID: 33506816      PMCID: PMC7924316          DOI: 10.3390/clinpract11010005

Source DB:  PubMed          Journal:  Clin Pract        ISSN: 2039-7275


  14 in total

1.  Treatment of hidradenitis suppurativa with a nonablative radiofrequency device.

Authors:  Julie Iwasaki; Diego E Marra; Edgar F Fincher; Ronald L Moy
Journal:  Dermatol Surg       Date:  2007-12-05       Impact factor: 3.398

2.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.

Authors:  C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-01-30       Impact factor: 6.166

3.  Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa.

Authors:  G B Jemec; P Wendelboe
Journal:  J Am Acad Dermatol       Date:  1998-12       Impact factor: 11.527

4.  Hidradenitis suppurativa.

Authors:  J Revuz
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-09       Impact factor: 6.166

5.  Effect of smooth pulsed light at 400 to 700 and 870 to 1,200 nm for acne vulgaris in Asian skin.

Authors:  Seiji Kawana; Rieko Tachihara; Tokue Kato; Tokuya Omi
Journal:  Dermatol Surg       Date:  2009-11-13       Impact factor: 3.398

6.  Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization.

Authors:  Paul G Hazen; Brent P Hazen
Journal:  Dermatol Surg       Date:  2009-12-21       Impact factor: 3.398

7.  Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF).

Authors:  Sophia Wilden; Marina Friis; Andrea Tuettenberg; Petra Staubach-Renz; Joanna Wegner; Stephan Grabbe; Esther von Stebut
Journal:  J Dermatolog Treat       Date:  2019-10-17       Impact factor: 3.359

Review 8.  Update on hidradenitis suppurativa: connecting the tracts.

Authors:  Liza Gill; Melissa Williams; Iltefat Hamzavi
Journal:  F1000Prime Rep       Date:  2014-12-01

9.  Effects of Intradermal Radiofrequency Treatment and Intense Pulsed Light Therapy in an Acne-induced Rabbit Ear Model.

Authors:  Joon Seok; Jong Hwan Kim; Jae Min Kim; Tae Rin Kwon; Sun Young Choi; Kapsok Li; Beom Joon Kim
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

10.  Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.

Authors:  Ester Del Duca; Paola Morelli; Luigi Bennardo; Cosimo Di Raimondo; Steven Paul Nisticò
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

View more
  1 in total

Review 1.  [Topical and novel device-based therapies for mild hidradenitis suppurativa].

Authors:  G Nikolakis; E von Stebut
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.